SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-298083"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-298083" > Blood-Pressure and ...

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease

Yusuf, Salim (författare)
McMaster Univ, Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada.;McMaster Univ, Dept Med, Hamilton, ON, Canada.
Lonn, Eva (författare)
McMaster Univ, Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada.;McMaster Univ, Dept Med, Hamilton, ON, Canada.
Pais, Prem (författare)
St Johns Res Inst, Bangalore, Karnataka, India.
visa fler...
Bosch, Jackie (författare)
McMaster Univ, Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada.;McMaster Univ, Sch Rehabil Sci, Hamilton, ON, Canada.
Lopez-Jaramillo, Patricio (författare)
Univ Santander, Fdn Oftalmol Santander, Bucaramanga, Colombia.;Univ Santander, Inst Masira, Sch Med, Bucaramanga, Colombia.
Zhu, Jun (författare)
Chinese Acad Med Sci, Fu Wai Hosp, Beijing 100730, Peoples R China.;Peking Union Med Coll, Beijing 100021, Peoples R China.
Xavier, Denis (författare)
St Johns Res Inst, Bangalore, Karnataka, India.;St Johns Med Coll, Bangalore, Karnataka, India.
Avezum, Alvaro (författare)
Dante Pazzanese Inst Cardiol, Sao Paulo, Brazil.
Leiter, Lawrence A. (författare)
Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.;Univ Toronto, St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada.
Piegas, Leopoldo S. (författare)
HCor Heart Hosp, Sao Paulo, Brazil.
Parkhomenko, Alexander (författare)
Inst Cardiol, Kiev, Ukraine.
Keltai, Matyas (författare)
Semmelweis Univ, Hungarian Inst Cardiol, H-1085 Budapest, Hungary.
Keltai, Katalin (författare)
Semmelweis Univ, Hungarian Inst Cardiol, H-1085 Budapest, Hungary.
Sliwa, Karen (författare)
Univ Cape Town, Hatter Inst Cardiovasc Res Africa, Dept Med, Soweto Cardiovasc Res Grp, ZA-7925 Cape Town, South Africa.
Chazova, Irina (författare)
Inst Clin Cardiol, Russian Cardiol Res Complex, Moscow, Russia.
Peters, Ron J. G. (författare)
Univ Amsterdam, Acad Med Ctr, Dept Cardiol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
Held, Claes (författare)
Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
Yusoff, Khalid (författare)
Univ Teknologi Majlis Amansh Rakyat, Selayang, Malaysia.;Univ Coll Sedaya Int Univ, Kuala Lumpur, Malaysia.
Lewis, Basil S. (författare)
Technion Israel Inst Technol, Ruth & Bruce Rappaport Sch Med, Lady Davis Carmel Med Ctr, Haifa, Israel.
Jansky, Petr (författare)
Univ Hosp Motol, Prague, Czech Republic.
Khunti, Kamlesh (författare)
Univ Leicester, Diabet Res Ctr, Leicester, Leics, England.
Toff, William D. (författare)
Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England.;Glenfield Hosp, Natl Inst Hlth Res, Leicester Cardiovasc Biomed Res Unit, Leicester, Leics, England.
Reid, Christopher M. (författare)
Monash Ctr Cardiovasc Res & Educ Therapeut, Primary Care Diabet & Vasc Med, Melbourne, Vic, Australia.;Curtin Univ, Sch Publ Hlth, Perth, WA 6845, Australia.
Varigos, John (författare)
Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia.
Accini, Jose L. (författare)
Univ Norte, Barranquilla, Colombia.
McKelvie, Robert (författare)
McMaster Univ, Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada.;McMaster Univ, Dept Med, Hamilton, ON, Canada.
Pogue, Janice (författare)
McMaster Univ, Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada.;McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
Jung, Hyejung (författare)
McMaster Univ, Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada.
Liu, Lisheng (författare)
Chinese Acad Med Sci, Fu Wai Hosp, Beijing 100730, Peoples R China.;Peking Union Med Coll, Beijing 100021, Peoples R China.
Diaz, Rafael (författare)
Inst Cardiovasc Rosario, Rosario, Santa Fe, Argentina.
Dans, Antonio (författare)
Univ Philippines, Coll Med, Manila, Philippines.
Dagenais, Gilles (författare)
Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada.
visa färre...
McMaster Univ, Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada;McMaster Univ, Dept Med, Hamilton, ON, Canada. St Johns Res Inst, Bangalore, Karnataka, India. (creator_code:org_t)
2016
2016
Engelska.
Ingår i: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 374:21, s. 2032-2043
Relaterad länk:
https://urn.kb.se/re...
visa fler...
https://doi.org/10.1...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • BACKGROUND Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of cardiovascular events substantially.METHODS In a trial with 2-by-2 factorial design, we randomly assigned 12,705 participants at intermediate risk who did not have cardiovascular disease to rosuvastatin (10 mg per day) or placebo and to candesartan (16 mg per day) plus hydrochlorothiazide (12.5 mg per day) or placebo. In the analyses reported here, we compared the 3180 participants assigned to combined therapy (with rosuvastatin and the two antihypertensive agents) with the 3168 participants assigned to dual placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included heart failure, cardiac arrest, or revascularization. The median follow-up was 5.6 years.RESULTS The decrease in the LDL cholesterol level was 33.7 mg per deciliter (0.87 mmol per liter) greater in the combined-therapy group than in the dual-placebo group, and the decrease in systolic blood pressure was 6.2 mm Hg greater with combined therapy than with dual placebo. The first coprimary outcome occurred in 113 participants (3.6%) in the combined-therapy group and in 157 (5.0%) in the dual-placebo group (hazard ratio, 0.71; 95% confidence interval [CI], 0.56 to 0.90; P=0.005). The second coprimary outcome occurred in 136 participants (4.3%) and 187 participants (5.9%), respectively (hazard ratio, 0.72; 95% CI, 0.57 to 0.89; P=0.003). Muscle weakness and dizziness were more common in the combined-therapy group than in the dual-placebo group, but the overall rate of discontinuation of the trial regimen was similar in the two groups.CONCLUSIONS The combination of rosuvastatin (10 mg per day), candesartan (16 mg per day), and hydrochlorothiazide (12.5 mg per day) was associated with a significantly lower rate of cardiovascular events than dual placebo among persons at intermediate risk who did not have cardiovascular disease. (ClinicalTrials.gov number, NCT00468923.)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy